FDA Fellowship - Orange Book NDA and ANDA Parenteral Combination Drug Product

FDA Fellowship - Orange Book NDA and ANDA Parenteral Combination Drug Product Center for Drug Evaluation and Research (CDER), United States about 7 hours ago

Location:

Silver Spring, MARYLAND

Deadline:

31 Jul 2026 •Applications will be reviewed on a rolling-basis.

FDA Office and Location:

Multiple research opportunities are available in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) located in White Oak, Maryland. The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. These efforts cover more than just medicines.

Research Project:

This project will examine approved letters and labeling to ensure that correct information for product listings is captured, research reference listed drug (RLD), reference standard (RS), therapeutic equivalence (TE) codes, and approval date information to support listings on the Orange Book website. Additionally, Orange Book publication information will be reviewed to support various types of special projects.

Learning Objectives:

Under the guidance of a mentor you will: Learn the structure and purpose of approved letters and product labeling in supporting regulatory documentation and public listings. Learn how to verify and ensure accurate capture of product listing information for the Orange Book website. Learn to research and confirm Reference Listed Drug (RLD), Reference Standard (RS), Therapeutic Equivalence (TE) codes, and approval date information. Learn to cross-reference regulatory documents and databases to ensure consistency and accuracy in publicly available records. Learn the importance of accurate drug listing information in promoting transparency, generic drug development, and regulatory decision-making. Learn various aspects of the Orange Book publication information to support miscellaneous projects as directed by the mentor or other designated staff members.

Mentor:

The mentor for this opportunity is Timothy Kim (t.kimfda.hhs.gov ). If you have questions about the nature of the research, please contact the mentor.

Anticipated Appointment Start Date:

2026. Start date is flexible and will depend on a variety of factors.

Appointment Length:

The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation:

The appointment is full time.

Participant Stipend:

The participant will receive a monthly stipend commensurate with educational level and experience.

Citizenship Requirements:

This opportunity is available to U.S. citizens only. This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits. Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at

FDA. OPM

can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years. FDA Ethics Requirements If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists . FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following: Non-employee nature of the ORISE appointment; Prohibition on ORISE Fellows performing inherently governmental functions; Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship; The fact that research materials and laboratory notebooks are the property of the FDA; ORISE fellow's obligation to protect and not to further disclose or use non-public information.